What Is Platelet-Rich Plasma Therapy

Platelet-rich plasma (PRP) therapy is a form of regenerative medicine that uses a concentrated preparation of a patient's own blood platelets to deliver supraphysiological doses of growth factors directly to injured or degenerating tissue. The preparation is obtained through a simple blood draw and centrifugation process that separates and concentrates platelets, which contain hundreds of bioactive proteins involved in tissue repair. PRP is injected into target sites such as joints, tendons, skin, or the scalp to accelerate healing and promote cellular regeneration.

Tissue degeneration is one of the central hallmarks of aging. Tendons lose elasticity, cartilage thins, wounds heal more slowly, and hair follicles miniaturize. These changes are not solely structural; they reflect a declining capacity for local growth factor signaling and reduced recruitment of progenitor cells. PRP therapy directly addresses this decline by reintroducing a concentrated bolus of the signaling molecules that orchestrate repair.

From a longevity perspective, PRP sits at the intersection of musculoskeletal preservation and functional independence. Joint deterioration and tendon injuries are among the leading causes of reduced mobility in the second half of life, and loss of mobility is itself a strong predictor of accelerated biological aging and mortality. Maintaining the integrity of connective tissues through targeted regenerative interventions may preserve the physical capacity that underpins healthspan. PRP's autologous nature (using the patient's own biology) also sidesteps many of the immunological concerns associated with exogenous cell therapies.

The process begins with a venous blood draw, typically 15 to 60 milliliters depending on the system used. This whole blood is placed into a centrifuge that spins at controlled speeds to separate the blood into layers: red blood cells settle to the bottom, a thin buffy coat of white blood cells and platelets forms in the middle, and platelet-poor plasma rises to the top. The platelet-rich layer is carefully extracted, yielding a concentrate that contains three to seven times the baseline platelet count per unit volume.

Platelets are not merely clotting agents. Their alpha granules store a dense payload of growth factors, including platelet-derived growth factor (PDGF), transforming growth factor beta (TGF-beta), vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF-1), and epidermal growth factor (EGF). When PRP is injected and platelets are activated (either by the collagen in native tissue or by an exogenous activator like calcium chloride), these granules degranulate and release their contents into the local microenvironment. The released growth factors bind to receptors on nearby cells, triggering intracellular signaling cascades that promote cell proliferation, extracellular matrix synthesis, angiogenesis, and chemotaxis of mesenchymal stem cells to the injury site.

The downstream biological effects vary by tissue. In tendons, PDGF and TGF-beta stimulate tenocyte proliferation and collagen type I synthesis, gradually remodeling disorganized scar tissue into more functional tendon architecture. In cartilage, growth factors reduce the activity of matrix metalloproteinases (enzymes that degrade cartilage) and upregulate proteoglycan production. In skin and scalp tissue, VEGF and EGF promote neovascularization and epithelial cell turnover, which is why PRP has found applications in wound healing, facial rejuvenation, and hair restoration. The inflammatory phase triggered by the injection itself also plays a role: a controlled, acute inflammatory response recruits macrophages that clear debris and further amplify the regenerative signaling cascade.

A PRP session typically begins with a standard venous blood draw from the arm, usually 15 to 60 milliliters depending on the system and the volume of PRP needed. The blood is processed in a centrifuge for 5 to 15 minutes while the treatment area is prepared. If the injection targets a joint or tendon, the practitioner may use ultrasound to visualize the anatomy and guide needle placement. The injection itself takes only a few minutes.

The entire visit, from blood draw to completion, typically lasts 45 to 90 minutes. Most patients experience moderate soreness at the injection site for one to three days afterward, which reflects the intended inflammatory response. Ice can be applied briefly for comfort, but prolonged icing and anti-inflammatory medications are generally discouraged because they may dampen the healing cascade PRP is designed to trigger. Light activity is usually permitted within a day or two, with a gradual return to full loading over the following weeks as directed by the treating clinician.

Most PRP protocols for musculoskeletal conditions involve a series of one to three injections spaced four to six weeks apart. This interval allows enough time for the biological response from each injection to progress through the inflammatory, proliferative, and early remodeling phases before the next dose is administered. Clinical reassessment is typically performed at three months post-treatment, with some patients experiencing continued improvement up to six months as tissue remodeling matures.

For maintenance in chronic conditions like osteoarthritis, some practitioners recommend repeat injections every six to twelve months based on symptom recurrence and functional status. Aesthetic applications such as hair restoration may follow a similar initial series with maintenance sessions two to three times per year. The optimal frequency and total number of treatments remain subjects of ongoing research, and individual variation in response means protocols are often adjusted based on clinical outcomes.

PRP therapy is typically not covered by insurance and is paid out of pocket. Costs per injection session generally range from $500 to $2,000 in the United States, with variation driven by geographic location, the practitioner's specialty and experience, the preparation system used, and whether image guidance (ultrasound or fluoroscopy) is included. A full series of three injections for a single joint may therefore total $1,500 to $6,000. Hair restoration PRP sessions tend to fall in the $500 to $1,500 range per session. Some clinics offer package pricing for a treatment series. Prospective patients should inquire about the specific preparation system, platelet concentration achieved, and whether the quoted price includes imaging guidance, as these factors affect both cost and quality of the procedure.

The evidence base for PRP varies considerably by indication. For knee osteoarthritis, multiple randomized controlled trials and several meta-analyses suggest that PRP injections can reduce pain and improve function compared to hyaluronic acid or saline injections, particularly in mild to moderate disease. For chronic tendinopathies, especially lateral epicondylitis (tennis elbow) and patellar tendinopathy, the evidence is moderately supportive, with some trials showing superior outcomes compared to corticosteroid injection at six to twelve months, though not all trials agree. For rotator cuff tendinopathy and Achilles tendinopathy, results are more mixed, with some studies showing benefit and others finding no significant difference from placebo injection.

In dermatological applications, small to mid-sized trials support PRP for androgenetic alopecia, showing increased hair density and thickness compared to placebo. Evidence for facial rejuvenation is more limited and largely based on smaller studies with shorter follow-up. A persistent challenge across PRP research is the lack of standardization: different centrifuge systems, spin protocols, platelet concentrations, leukocyte content (leukocyte-rich versus leukocyte-poor preparations), and activation methods make it difficult to compare results across studies. This heterogeneity means that a positive trial using one preparation system does not automatically validate all PRP products. Larger, well-controlled trials with standardized protocols remain needed to clarify optimal preparation methods and identify which patient populations benefit most.

PRP carries a low risk profile because it is autologous, meaning immunological reactions and disease transmission are not significant concerns. The most common adverse effects are injection-site pain, swelling, and bruising, which typically resolve within days. Infection is rare but possible with any injection procedure. PRP is generally avoided in individuals with thrombocytopenia, active infection at the treatment site, or certain blood disorders. Patients taking anticoagulant or antiplatelet medications need careful evaluation. Results are not uniform; some individuals respond well while others experience minimal benefit, and the lack of standardized preparation protocols means outcomes can vary between practitioners and systems. Insurance coverage is uncommon, so financial considerations are relevant.